Tuesday 5th November 2019
Dr Tracey Frech, the director of the systemic sclerosis (SSc) clinic at the University of Utah, and Salt Lake Veterans Affair Medical Centre, focussed her talk at the Cambridge conference on gut involvement in systemic sclerosis and the importance of research in this subject area.
Wednesday 30th October 2019
The theme of Dr Voon Ong’s talk at SRUK’s Cambridge Conference in July was clinical trials in the field of emerging therapies, providing an overview of the latest news from recently completed clinical studies and of ongoing studies that show significant promise.
Friday 25th October 2019
Close to 70% of people living with systemic sclerosis develop interstitial lung disease, which often takes the form of pulmonary fibrosis. Recent research into protein inhibitors may lead to new therapeutic agents to treat pulmonary fibrosis.
Monday 23rd September 2019
Botox surgery is emerging as a form of treatment for Raynaud’s phenomenon, but the reasoning behind why this may work remains unclear. Research evaluating the use of Botulinum toxin type A (BoNT/A), one of the the main ingredients of Botox, has been steadily building since the early 2000s.
Friday 13th September 2019
In an exciting step for scleroderma treatment, the USA’s Food and Drug Administration (FDA) have approved the use of nintedanib in treating interstitial lung disease associated with systemic sclerosis, making this the first therapy for those living with this condition caused by lung fibrosis.
Friday 30th August 2019
A recent review published in Nature Rheumatology focused on research into the classification of scleroderma, which suggests that the current classification does not capture the heterogeneity of the condition.
Thursday 22nd August 2019
In her talk at SRUK’s regional conference in Cambridge, Dr Robyn Domsic discussed a variety of topics that are crucial to understanding vascular involvement and expert recommendations on management.
Tuesday 20th August 2019
Recently, a poll was run online to understand what oral and dental complications of scleroderma impact those living with the condition the most. We’ve selected some questions from the poll to answer here.
Thursday 27th June 2019
Given the role that the lymphatic system plays with the immune system, it has been speculated that lymphatic dysfunction may encourage the development of rheumatic autoimmune diseases, such as scleroderma, lupus and rheumatoid arthritis.
Friday 21st June 2019
Fibrosis is one of the major physical changes that a person living with scleroderma can experience. Its effects are potentially extremely damaging and widespread in the body, it is critical that biomarkers are defined to predict if certain individuals are at risk of developing fibrosis.
